Today, Kenyatta University Teaching, Referral & Research Hospital (KUTRRH) has become the first public hospital in the region to deliver Lutetium-177 PSMA targeted radiation therapy – a significant development for patients with advanced prostate cancer.
This therapy utilizes a radioactive element, Lutetium-177, that is bound to a molecule with high affinity for Prostate-Specific Membrane Antigen (PSMA) — a protein that is highly expressed in prostate cancer cells. The therapeutic form of radiation is delivered directly to the cancer cells while sparing normal tissues from harm. This novel therapy provides new hope for patients whose disease has advanced despite conventional therapies such as hormone therapy or chemotherapy.
“This advancement showcases KUTRRH’s dedication to providing world-class cancer treatment in a public institution,” said KUTRRH CEO, Dr. Zeinab Gura.
“This new treatment allows more patients with advanced prostate cancer to access life-extending personalised care in our local community, without travelling internationally.”Lutetium-177 PSMA therapy is recommended for patients with advanced or metastatic prostate cancer, patients whose disease has progressed after hormone therapy, or patients who are receiving chemotherapy or are unable to tolerate chemotherapy. Prior to therapy, patients at KUTRRH have a PSMA scan to assess suitability for the treatment. KUTRRH continues to invest in latest oncology technology to improve outcomes and increase access for affordable cancer care for all patients.